FDA Bids Farewell to Cepheid's COVID Test Era
Published Date: 6/26/2025
Notice
Summary
The FDA is ending the emergency approval for Cepheid’s Xpert Xpress COVID-19 test because the company asked them to. This means the test can no longer be used under emergency rules, so labs and healthcare providers need to switch to other authorized tests. No extra costs or deadlines for the public, but it’s a heads-up for anyone using this test.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Cepheid Xpert Xpress EUA Revoked
The FDA revoked the Emergency Use Authorization for Cepheid’s Xpert Xpress SARS-CoV-2 test at the company's request. That means labs and health care providers can no longer use this test under emergency rules and must switch to other authorized COVID-19 tests.
No Public Costs or Deadlines
The FDA says there are no extra costs or new deadlines for the public because of this revocation. This notice is mainly a heads-up for people and organizations that were using the Cepheid test.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-11820, Public Water System Supervision Program Revision for New York; Notice of Approval and Opportunity for Public Comment and Public Hearing
New York updated its water safety rules to better control harmful chemicals in drinking water. The EPA says these changes meet all federal standards and is ready to approve them. If you live in New York or care about clean water, you can share your thoughts or ask for a public hearing soon.
Next: 2025-11823, Meeting of the Interagency Task Force on Veterans Small Business Development
The Interagency Task Force on Veterans Small Business Development is meeting soon to discuss new ways to help veteran-owned small businesses grow and succeed. If you’re a veteran entrepreneur, this means fresh ideas and support could be on the way, with updates coming soon. Stay tuned for opportunities that might boost your business and open doors to new resources!